EMBARGOED FOR RELEASE
Tuesday, June 7, 2011
Elizabeth Laur, (414) 276-2145, firstname.lastname@example.org
MDS Press Room: Metro Toronto Convention Centre, South Building, Room 705
Note to media: See abstract 385
Inhaled apomorphine reduces 'off' periods in Parkinson's disease
TORONTO - A study assessing the safety, efficacy, and tolerability of inhaled apomorphine to treat "off" periods in patients with Parkinson's disease (PD) was presented today at The Movement Disorder Society's 15th International Congress of Parkinson's Disease and Movement Disorders.
Reducing "off" time is a key aim in PD, but becomes difficult as the disease progresses. Although apomorphine is effective as a subcutaneously injection, Dr. Katherine Grosset of the Institute of Neurological Sciences, Glasgow, UK investigates non-invasive oral inhalation for potential additional advantages of improved safety, local tolerability and rapid benefit.
Inhaled apomorphine was tested under double-blind, placebo-controlled, randomized conditions in PD patients with motor fluctuations and recognizable "off" periods. Four ascending doses of the investigational product in a pre-metered inhaler were tested in the clinic to establish therapeutic benefit. The patient then administered this dose at home for 4 weeks to abort "off" episodes. Results demonstrate that PD patients experienced significant improvement in the UPDRS III for apomorphine than the placebo. They also experienced reduced "off" periods and more aborted "off" periods.
Andrew Lees, MD, FRCP, of Reta Lila Weston Institute of Neurological Studies in, London states, "Inhaled apomorphine is a quick-acting, reliable rescue device for patients with debilitating 'off' periods in Parkinson's disease. If further trials confirm its long term safety then it is likely to replace subcutaneous apomorphine injections and also be suitable for patients who are unable or unwilling to inject themselves."
About the 15th International Congress of Parkinson's Disease and Movement Disorders:
Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options for Movement Disorders, including Parkinson's disease. More than 3,200 physicians and medical professionals from 74 countries will be able to view over 1,100 scientific abstracts submitted by clinicians from around the world.
About The Movement Disorder Society:
The Movement Disorder Society, an international society of over 3,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about The Movement Disorder Society, visit www.movementdisorders.org.